Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HQH vs HQL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HQH Wins Head-to-Head Institutional Verdict (1–0 across 6 Pillars · 3–0 Matrix Metrics)

HQH Overall Winner 6-Pillar Tally: HQH 1 – 0 HQL (5 Tie) Matrix Metrics: HQH 3 – 0 HQL

As of Nov 16, 2026, abrdn Healthcare Investors (HQH) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). HQH carries a Unified Composite Score of 48.3/100 (HOLD) at $21.11 (N/M Forward P/E, N/A operating margin), whereas HQL carries 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: HQH is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9); meanwhile HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HQH vs HQL
HQH NYSE Head-to-Head Winner
abrdn Healthcare Investors
Institutional Equity
$21.11
-1.49% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.88β · 40% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -4.3%) with fading momentum, RSI 50
RSI-14: 49.9 · SMA20: $21.03 · SMA50: $20.81
HQL NYSE
abrdn Life Sciences Investors
Institutional Equity
$17.81
-2.57% 1D
Market Cap $455.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.91β · 39% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.5 · SMA20: $18.16 · SMA50: $18.45

6-Pillar Scorecard Institutional Category Breakdown (HQH 1 – 0 HQL)

Columns: Metric · HQH · HQL
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale HQH
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $1.0B $455.0M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HQH (3) vs HQL (0)
Institutional Metric HQH HQL Criterion Row Edge
Market Capitalization
Scale
$1.0B $455.0M Larger Scale HQH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
52% ($17–$25) 31% ($16–$23) Stronger Trend HQH
Beta / 30D Volatility
Risk Regime
0.88β · 40% Vol 0.91β · 39% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite HQH
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HQH +5.08 pp
HQH: +11.22% · HQL: +6.14%
3M Horizon HQH +6.03 pp
HQH: -11.97% · HQL: -18.0%
6M Horizon HQH +6.37 pp
HQH: +7.16% · HQL: +0.79%
1Y Horizon HQH +7.29 pp
HQH: +13.49% · HQL: +6.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HQH vs HQL. Trailing 12-month operating profitability (HQH N/A vs HQL N/A) and valuation multiples (HQH N/M vs HQL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HQH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
HQL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HQH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HQH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HQL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HQL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HQH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $1.0B market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HQL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $455.0M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HQH vs HQL Key Questions & Quantitative Answers

As of Nov 16, 2026, abrdn Healthcare Investors (HQH) is the stronger overall head-to-head candidate over abrdn Life Sciences Investors (HQL) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). HQH carries a Unified Composite Score of 48.3/100 (HOLD) at $21.11 (N/M Forward P/E, N/A operating margin), whereas HQL carries 46.0/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: HQH is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9); meanwhile HQL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HQH leads the Growth & Scale pillar: HQH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HQL at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HQH generates N/A in USD-normalized revenue versus N/A for HQL. In operating R&D and SG&A reinvestment, HQH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for HQL.

HQH and HQL trade at balanced relative valuation multiples. HQH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HQL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQH (N/A ROE) versus HQL (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HQH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.88β · 40% Vol realized risk). By comparison, HQL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.